Perimenopause and Heart Risk: It’s Not About the Number on Your Scale
“My weight hasn’t really changed, but everything feels different.” I hear this almost every week, and every time, I know exactly what we’re going to find. The woman sitting across from me is in her late 40s or early 50s. Her clothes fit differently. Her waist is larger. Energy has dropped. Her cholesterol and fasting insulin are creeping in the wrong direction. Her doctor told her she’s fine because her weight is the same. Nobody explained perimenopause heart risk to her. Nobody told her that during this transition, her body is shifting fat in a way that changes her heart health path, often without any major change in scale weight at all.
New research published in 2026 in the American Journal of Preventive Cardiology puts this process on the record clearly. Perimenopause is an “obesogenic sensitive period,” meaning it creates metabolic and hormonal conditions that actively promote fat redistribution toward visceral storage, even in women who are not gaining significant weight. And visceral fat, the fat stored around the organs deep in the abdomen, drives a cascade of metabolic changes that directly elevate heart risk.
This is not a new observation in my practice. I’ve been seeing it for years. What’s new is the quality and specifics of the evidence, and the clear roadmap it provides for identifying and acting before heart risk becomes heart disease. Perimenopause is a window. The question is whether your provider is treating it as one.
How Perimenopause Heart Risk Begins: The Fat Redistribution Story
During reproductive years, estrogen directs fat storage toward the hips, thighs, and buttocks: surface fat that stays relatively inactive. As estrogen levels begin to fluctuate and decline during perimenopause, this directing function weakens. Fat storage shifts. The body begins building up visceral fat, the deep belly fat that wraps around the liver, pancreas, intestines, and heart.
This shift is not driven by eating more. The 2026 American Journal of Preventive Cardiology review, led by Manning, Stockman, and Zanni, documents that even women with minimal-to-modest weight gain during perimenopause experience significant expansion of visceral fat alongside loss of surface fat in the hips and thighs.
Here’s what that means: a woman’s scale weight may tell one story, but her body composition tells a very different one. This is the biological root of perimenopause heart risk.
Why Visceral Fat Is the Core of Perimenopause Heart Risk
Visceral fat is not inert storage tissue. It actively releases free fatty acids into the blood supply flowing directly to the liver. This fat-to-liver delivery drives liver insulin resistance, meaning the liver becomes less responsive to insulin’s signal to stop producing glucose.
As a result, the pancreas pumps out more and more insulin trying to compensate. High circulating insulin drives further fat buildup, making it harder to lose weight and easier to gain it. On top of that, visceral fat releases inflammation chemicals that drive arterial inflammation, a root cause of artery plaque and heart disease.
Translation: perimenopause heart risk is the downstream consequence of estrogen fluctuation driving visceral fat expansion, which then drives insulin resistance and arterial inflammation. It is a documented biological pathway, and conventional medicine is still slow to recognize it.
Perimenopause Heart Risk in My Practice
In conventional care, a woman in her late 40s goes to her doctor, her weight is normal or near normal, her fasting glucose is in range, and she gets a clean bill of health. Three years later, her fasting insulin is elevated, her LDL is higher, her triglycerides have climbed, and her blood pressure has ticked up. Nobody connected those dots to the perimenopausal transition she started three years ago. Nobody named the perimenopause heart risk that was accumulating the whole time.
I’ve seen this pattern hundreds of times. The problem is not the individual doctor. The problem is a system that doesn’t use the right tests or ask the right questions at the right time.
The markers I look at in a woman during perimenopause include fasting insulin, not just fasting glucose. Fasting insulin rises years before fasting glucose becomes abnormal. By the time glucose is elevated, real metabolic damage has already built up. I also look at triglyceride-to-HDL ratio as a stand-in marker for insulin resistance, waist circumference as a visceral fat proxy, and high-sensitivity CRP as an inflammation marker.
These are not exotic tests. They are available everywhere. They simply go unordered because the framework connecting perimenopause, visceral fat, and heart risk is not being applied in most primary care settings.
The Muscle Mass Component
The 2026 review also documents that perimenopause speeds up skeletal muscle loss beyond what normal aging causes. This matters for heart and metabolic risk in two ways.
Skeletal muscle is the body’s primary site of glucose uptake after eating. Less muscle means less glucose is cleared from the bloodstream after meals, pushing the body toward post-meal glucose spikes and worsening insulin resistance. Additionally, lower muscle mass reduces resting metabolic rate, making weight management progressively harder and visceral fat accumulation more likely.
This is why I tell every woman in perimenopause in my practice: resistance training is not optional at this stage of life. It is metabolic medicine. Preserving and building muscle mass directly counters the perimenopause shift toward visceral fat and insulin resistance.
What You Should Be Asking Your Doctor About Perimenopause Heart Risk
If you are in your late 40s or early 50s, particularly if your menstrual cycle has started to change, here is what your annual workup should include alongside standard cholesterol panels: fasting insulin, high-sensitivity CRP, waist circumference, and ideally a body composition assessment to distinguish fat mass from lean mass. Quantifying your perimenopause heart risk in measurable terms is the whole point of this kind of workup.
If your doctor tells you everything looks fine based on your weight and basic lipid panel, ask specifically about fasting insulin and inflammation markers. These numbers often tell a different story during perimenopause, and identifying the shift early is the entire point.
The 2026 research frames perimenopause as a sensitive period, which means the interventions you put in place now, hormone support, resistance training, targeted nutrition, and sleep optimization, have an outsized effect compared to the same interventions applied later. At Living Well Dallas, we build these panels into every perimenopausal evaluation. Menrva Health provides the same comprehensive workup through telehealth if you’re not in the Dallas area. This window opens during perimenopause. The goal is to use it.
Key Takeaways
- Perimenopause drives visceral fat buildup even in women who are not gaining significant weight, due to shifts in how estrogen directs fat storage.
- Visceral fat releases free fatty acids that drive liver insulin resistance and excess insulin production, directly elevating heart risk.
- Standard lab panels often miss early metabolic changes during perimenopause; fasting insulin and high-sensitivity CRP are more sensitive early markers.
- Perimenopause also speeds up skeletal muscle loss beyond normal aging, worsening insulin resistance and making visceral fat buildup worse.
- Perimenopause is a “sensitive period” when targeted lifestyle and hormone support have high impact; early action matters.
Frequently Asked Questions
Can I be at heart disease risk if my weight hasn’t changed during perimenopause? Yes. The 2026 American Journal of Preventive Cardiology review documents that even women with minimal weight gain during perimenopause experience significant shifts in fat distribution from surface storage to visceral storage. Visceral fat drives insulin resistance and arterial inflammation regardless of what the scale says. A normal weight does not mean a normal metabolic risk profile during this transition.
What tests should a woman in perimenopause ask for? Standard lipid panels and fasting glucose are not sufficient to capture the metabolic changes of perimenopause. Ask specifically for fasting insulin, high-sensitivity CRP (a marker of arterial inflammation), and a triglyceride-to-HDL ratio (a reliable insulin resistance indicator). Waist circumference during your exam also gives useful information about visceral fat buildup that body weight alone does not capture.
Hormones, Metabolism, and Heart Health
Does estrogen directly affect heart risk? Estrogen plays a direct role in fat distribution, arterial health, and metabolic function. As estrogen levels fluctuate and decline during perimenopause, visceral fat builds up, insulin resistance increases, and arterial inflammation rises. The relationship is not indirect. Estrogen regulates metabolic pathways that, when disrupted, produce the heart risk pattern documented in this 2026 research.
Can hormone therapy reduce perimenopause heart risk? Research suggests that hormone therapy initiated during the early years of menopause, when the heart health environment is still relatively good, may reduce some of the metabolic changes of the transition. A separate 2025 meta-analysis from The Menopause Society found that hormone therapy significantly reduces insulin resistance. Timing, formulation, and individual health factors all shape the risk-benefit calculation. This is a conversation worth having with a clinician who understands the full evidence.
Exercise and Nutrition During Perimenopause
Why does resistance training matter so much during perimenopause? Skeletal muscle is the body’s primary site of post-meal glucose uptake. Muscle loss in perimenopause reduces this capacity, worsening insulin resistance and driving visceral fat buildup. Resistance training builds and preserves muscle mass, directly countering the perimenopause metabolic shift. It is not extra care for this transition. It is central to it.
What dietary changes matter most for perimenopause heart health? Reducing refined carbs and sugar is the most impactful dietary intervention for addressing insulin resistance during perimenopause. Prioritizing protein at every meal supports muscle retention. Anti-inflammatory eating patterns, specifically those emphasizing vegetables, omega-3 fats, and fiber, address the visceral fat-driven inflammation that drives heart risk. These are not general wellness tips. They are targeted interventions for the specific metabolic changes this phase of life produces.
Dr. Betty’s Bottom Line
Perimenopause is not a dramatic event. It is a slow transition, and that is exactly what makes it dangerous. Women gain a few pounds, their waist changes, their labs creep in the wrong direction. Their doctor says everything looks fine. Years pass. By the time someone connects the dots to perimenopause heart risk, that risk has been building quietly for years.
I don’t find this acceptable. We have the tools to identify this transition early, we have markers that show where metabolism is heading before clinical disease appears, and we have interventions that work: targeted hormone support, resistance training, strategic nutrition, and sleep optimization. The 2026 research in the American Journal of Preventive Cardiology doesn’t give us anything we didn’t already know in practice. What it does is make the case more rigorously than it’s been made before.
If you’re in perimenopause, or if your cycles have started to change, I want to look at your full metabolic picture. Not just your weight. Not just your standard cholesterol panel. The actual picture. That’s the work we do at Living Well Dallas and Menrva Health, and it’s the kind of care that changes long-term health trajectories.
In-person care at Living Well Dallas is available for patients in the Dallas area. Menrva Health offers comprehensive metabolic and hormone evaluation through telehealth in all 50 states.
Source: Manning ME, Stockman SL, Zanni MV. Perimenopause as an Obesogenic Sensitive Period: Contributions to Elevated Cardiovascular Risk. Am J Prev Cardiol. 2026;26:101398. PMID:41567597. PMC12818170.